microdosing glp-1 menopause Postmenopausal women on the medication tirzepatide (Zepbound) for obesity lost more weight if they were also using hormone therapy, a retrospective cohort study indicated. https://www.medpagetoday.com/endocrinology/menopause/119594 GLP-1 Agonists in Perimenopause: Unique

GILZ as a regulator of cell fate and inflammation

Eating, especially carbohydrates, within 2 hours of injection blunts GH release by raising insulin

Here, we provide a concise overview of the pharmacology and design of ADCs and we particularly review advances in ADCs directed against HER2 (human epidermal growth factor receptor 2), HER3, TROP2 (trophoblast cell-surface antigen 2), MET (mesenchymal-epithelial transition receptor) and CEACAM5 (carcinoembryonic antigenrelated cell adhesion molecular 5) in NSCLC

Peptide Therapy: An Overview Peptide therapy involves the use of specific peptides to regulate and enhance various physiological processes in the body

It completed Phase 2 trials in obesity [3] and type 2 diabetes [4] and moved into a Phase 3 program (TRIUMPH)